JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Therapeutic Mechanisms and Pharmacological Actions of Incretin-Based Dual and Single Receptor Agonists

Jyothika Taneti*, Sridevi Korimelli

Department of Pharmacology, School of Pharmaceutical Sciences and Technologies, JNTU, Kakinada, Andhra Pradesh, India

Publication history: Received on 9th April 2026; Revised on 16th May 2026; Accepted on 17th May 2026

Article DOI: 10.69613/ne8s3v59

Abstract: Postprandial glycemic regulation and systemic energy homeostasis depend heavily on enteroendocrine hormones secreted in response to nutrient ingestion. The clinical development of glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor co-agonists has transformed treatment paradigms for type 2 diabetes mellitus and chronic obesity. Therapeutic agents like semaglutide and tirzepatide achieve exceptional glycemic control, significantly lowering glycated hemoglobin levels while driving profound, dose-dependent body weight reductions. However, the therapeutic benefits of these highly effective molecules are frequently compromised by dose-limiting toxicities. Gastrointestinal adverse events, primarily manifesting as nausea, vomiting, diarrhea, and constipation, exhibit a strict dose-dependent profile that restricts rapid dose escalation and compromises therapeutic retention. Managing these clinical interventions necessitates navigating a delicate trade-off between maximizing metabolic benefits and maintaining patient tolerability. Gradual, individualized dose titration is the primary clinical strategy to minimize gastrointestinal discomfort and preserve patient adherence. Beyond glycemic control, dual-receptor co-agonism drives metabolic improvements by activating central satiety pathways, modulating gastric emptying kinetics, and inducing white adipose tissue browning and adipogenesis. This review discusses the physiological differences, comparative trial data, and tolerability trade-offs governing incretin-based pharmacotherapies. Optimizing long-term metabolic outcomes requires integrating patient-centered management strategies that balance receptor activation kinetics against individual tolerability thresholds, ensuring sustained therapeutic efficacy without excessive treatment discontinuation.

Keywords: Incretin therapy; Type 2 diabetes mellitus; Obesity; Tirzepatide; Semaglutide; Efficacy–tolerability trade-off.

1. Introduction

Type 2 diabetes mellitus (T2DM) and chronic obesity have become a global metabolic crisis. The global prevalence of obesity has nearly tripled over the past five decades, serving as a primary driver for the escalating incidence of T2DM [1]. Obesity functions as the premier pathogenic driver for insulin resistance, wherein ectopic lipid deposition in skeletal muscle, hepatocytes, and visceral fat depots impairs insulin receptor autophosphorylation and downstream intracellular signaling cascades [2]. Data indicate that approximately 80% to 90% of individuals diagnosed with T2DM are classified as either overweight or obese [3]. A body mass index (BMI) in the obese range is associated with a seven-fold increase in the risk of developing type 2 diabetes compared to a BMI within the normal range, while being overweight increases the risk three-fold [3].

The pathophysiology of these co-occurring disorders is characterized by a state of chronic, low-grade systemic inflammation initiated by adipocyte hypertrophy and hyperplasia [1,4]. Hypertrophic adipocytes experience hypoxic stress, triggering the recruitment of pro-inflammatory M1 macrophages and the subsequent hypersecretion of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) [2]. This pro-inflammatory microenvironment worsens hepatic insulin resistance and accelerates pancreatic β-cell exhaustion, culminating in glucose intolerance and overt hyperglycemia. The combination of obesity and T2DM multiplies the risk of developing a spectrum of metabolic comorbidities, including major adverse cardiovascular events (MACE), hypertension, atherogenic dyslipidemia, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis (MASH) [2,4].

Historically, pharmacological options for the management of obesity and glycemic control were restricted by sub-optimal efficacy, poor long-term safety profiles, and high treatment attrition rates [4]. Early-generation anti-obesity medications, such as centrally acting sympathomimetic stimulants or peripherally acting lipase inhibitors, achieved modest weight reductions and were frequently

* Corresponding author: Jyothika Taneti

discontinued due to adverse cardiovascular, neuropsychiatric, or gastrointestinal reactions [4]. Similarly, traditional antidiabetic regimens including sulfonylureas, meglitinides, and exogenous insulin frequently induced substantial weight gain and increased the incidence of severe hypoglycemia, complicating patient adherence and limiting therapeutic success [3].

The identification of the incretin effect, representing the significantly greater insulin secretory response observed after oral glucose administration compared to an identical intravenous glucose load, marked a paradigm shift in metabolic medicine [5,6]. Under normal physiological conditions, the gut-derived peptides GLP-1 and GIP account for up to 70% of the total postprandial insulin secretion [6]. In patients with T2DM, this incretin effect is significantly blunted, marked by a progressive impairment of GIP-stimulated insulin secretion and a reduction in postprandial GLP-1 levels [5].

The therapeutic exploitation of these pathways began with the development of dipeptidyl peptidase-4 (DPP-4) inhibitors and short-acting GLP-1 receptor agonists [4,7]. However, the development of long-acting, acylated peptide formulations, such as once-weekly semaglutide, and dual-acting co-agonists, such as tirzepatide, has revolutionized metabolic medicine [4,7]. These modern agents achieve sustained, supraphysiologic receptor activation, driving robust glycemic control and unprecedented levels of weight loss that approach the efficacy of bariatric surgery.

2. Incretin Physiology and Molecular Action

2.1. GLP-1 Synthesis and Secretion

Glucagon-like peptide-1 is a 30-amino-acid peptide derived from the post-translational processing of the preproglucagon gene, primarily by prohormone convertase 1/3 (PC 1/3) in the enteroendocrine L cells of the distal ileum and colon [7]. Nutrient ingestion, particularly rich in long-chain fatty acids and simple carbohydrates, triggers biphasic GLP-1 release into the portal circulation [8]. The active, circulating forms of the peptide exist as truncated GLP-1(7-36)amide and GLP-1(7-37), which exhibit equivalent insulinotropic potency [9].



Figure 1. Endogenous GLP-1 Biosynthesis

Upon release, GLP-1 binds to the glucagon-like peptide-1 receptor (GLP-1R), a class B1 G-protein-coupled receptor (GPCR) highly expressed on pancreatic β-cells, as well as in the gastrointestinal tract, kidneys, myocardium, and specific brain regions including the hypothalamus and solitary tract [7]. Ligand binding induces a conformational change that promotes coupling to the stimulatory G-protein subunit (Gs), stimulating adenylate cyclase and rapidly raising intracellular cyclic adenosine monophosphate (cAMP) levels [9].



Figure 2. Physiological pathway of endogenous glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) from localized tissue synthesis and triggers to rapid systemic enzymatic clearance by dipeptidyl peptidase-4 (DPP-4) and metabolic target organ dynamics.

This increase activates protein kinase A (PKA) and exchange protein directly activated by cAMP 2 (EPAC2), initiating a signaling cascade that closes ATP-sensitive potassium (KATP) channels and opens voltage-gated calcium channels (VDCCs) [8]. The resulting influx of extracellular calcium (Ca^{2+}) triggers the exocytosis of insulin-containing secretory vesicles from the β-cell [8].

This insulinotropic action of GLP-1 is strictly glucose-dependent, occurring only when plasma glucose levels exceed approximately 4.0mmol/L, thereby minimizing the risk of treatment-induced hypoglycemia [5]. Simultaneously, GLP-1R activation on pancreatic α-cells suppresses glucagon secretion during hyperglycemic and euglycemic states, reducing hepatic gluconeogenesis and glycogenolysis [5,7]. Extra-pancreatic actions of GLP-1 include the inhibition of gastric motility and acid secretion via vagally mediated pathways, slowing gastric emptying and attenuating postprandial glucose excursions [7]. In the central nervous system, GLP-1 activates receptors in the arcuate nucleus to enhance satiety, suppress appetite, and reduce caloric intake [5].

2.2. GIP Synthesis and Secretion

Glucose-dependent insulinotropic polypeptide is a 42-amino-acid peptide processed from a 153-amino-acid proprotein encoded by the GIP gene [8]. It is synthesized and secreted by enteroendocrine K cells located primarily in the proximal small intestine, including the duodenum and jejunum [8]. The secretion of GIP is stimulated by the absorption of lipids, carbohydrates, and amino acids, mediated by sodium-coupled glucose transporter 1 (SGLT-1) and fat-sensing receptors [8].

The GIP receptor (GIPR) is also a class B1 GPCR, expressing predominantly on pancreatic β-cells, α-cells, adipose tissue, osteoblasts, osteocytes, and specific nuclei within the central nervous system, including the hypothalamus and area postrema [8,10]. Similar to the GLP-1R, GIPR activation on β-cells stimulates the Gs-cAMP-PKA/EPAC2 pathway to augment glucose-dependent insulin secretion [8,10].

However, GIP exhibits distinct physiological features from GLP-1. Crucially, GIP displays glucagonotropic activity during periods of hypoglycemia and euglycemia [10]. Under low-glucose conditions, GIP acts directly on pancreatic α-cells to stimulate glucagon secretion, serving as a physiological counter-regulatory mechanism to prevent severe hypoglycemia [8,10]. Under hyperglycemic conditions, this glucagonotropic effect is blunted, and the insulinotropic effect dominates, supplemented by the paracrine inhibitory actions of insulin on α-cells [10].

In adipose tissue, GIPR signaling promotes lipid storage by increasing blood flow, stimulating lipoprotein lipase (LPL) activity, and enhancing insulin-mediated lipogenesis while suppressing glucagon-mediated lipolysis [10]. This anabolic pathway assists in lipid storage under normal physiological conditions, preventing ectopic lipid deposition [10].

2.3. Cooperative Mechanisms and Islet Microenvironment Integration

While native GIP displays minimal efficacy when administered as a monotherapy in patients with established T2DM due to receptor downregulation induced by chronic hyperglycemia, its therapeutic potency is fully restored upon the correction of glucose levels [10]. The rationale for dual GIPR/GLP-1R co-agonism relies on the distinct, complementary cellular kinetics of these two incretins. While both hormones signal via Gs-coupled pathways, GIPR activation exhibits faster receptor internalization and recycling dynamics compared to the GLP-1R, preventing receptor desensitization and sustaining intracellular signal transduction [10].

Dual receptor activation coordinates the islet microenvironment [8]. Co-agonism maximizes insulin secretion from β-cells via synergistic actions on the cAMP pathway [8]. In α-cells, the glucagonotropic action of GIP at lower glucose thresholds protects against insulin-induced hypoglycemia, while the potent glucagon-suppressive effects of GLP-1 dominate during hyperglycemic phases [10]. This balanced, bidirectional regulation provides stable glycemic control and a wide therapeutic index. In the central nervous system, the co-activation of GIPR and GLP-1R on distinct neuronal populations in the hypothalamus and hindbrain achieves synergistic reductions in appetite and food intake, while mitigating the central nausea responses typically triggered by high-dose GLP-1R activation [5,10].

3. Pharmacological Dynamics of Modern Incretin Agonists

3.1. Structural Modifications and Molecular Profiles

To overcome the rapid degradation of endogenous GLP-1 and GIP by the ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4), which restricts their natural half-lives to 1-2minutes and 5-7minutes respectively, chemical modifications have been engineered to extend therapeutic half-lives to support once-weekly administration [7,8].

3.1.1. Semaglutide

Semaglutide is a human GLP-1 analogue engineered with several modifications to achieve a half-life of approximately 7days [7]. The native alanine at position 8 is replaced with α-aminoisobutyric acid (Aib), which provides steric hindrance against DPP-4-mediated cleavage [9]. Lysine at position 26 is modified by the attachment of a hydrophilic spacer (consisting of two 8-amino-3,6-dioxaoctanoic acid molecules and a glutamic acid linker) connected to a C18 fatty diacid chain [7,9]. This lipid side chain facilitates strong, reversible binding to human serum albumin, protecting the peptide from renal clearance and extending its metabolic stability [9]. The native lysine at position 34 is replaced with arginine to prevent accidental acylation at this alternative site during synthesis [7].

Table 1. Structural and Pharmacokinetic Characteristics of Modern Incretin Agonists

Pharmacochemical Parameter	**Semaglutide [9]**	**Tirzepatide [2, 10]**
Peptide Backbone	Human GLP-1(7-37) analogue sequence with 94% structural homology to native human glucagon-like peptide-1	Synthetic, single-molecule peptide consisting of 39 amino acids structurally based on the native human GIP sequence
Primary Chemical Modifications	Alanine replacement with alpha-aminoisobutyric acid (Aib) at position 8; lysine replacement with arginine at position 34	Inclusion of non-standard Aib residues at positions 2 and 13 to protect against enzymatic cleavages
Acylation and Albumin Binding	Hydrophilic spacer and a C18 fatty diacid chain attached to the lysine residue at position 26	C20 fatty diacid moiety connected via a hydrophilic linker (gamma-Glu-2xAdo) to a lysine residue at position 20
Receptor Selectivity Profile	Highly selective, high-affinity glucagon-like peptide-1 receptor (GLP-1R) agonist	Dual agonist exhibiting balanced native-like affinity for GIPR and approximately 100-fold lower affinity for GLP-1R
Elimination Half-Life ($t_{1/2}$)	Approximately 7 days, facilitating stable once-weekly therapeutic dosing	Approximately 5 days, enabling sustained dual-receptor activation with once-weekly administration
Molecular Weight & Formula	$C_{187}H_{291}N_{45}O_{59}$; approximately 4113.58 Da	$C_{225}H_{348}N_{48}O_{68}$; approximately 4813.45 Da
Clinical Delivery Route	Subcutaneous injection (once weekly) or oral tablet formulation (once daily)	Subcutaneous injection (once weekly)

3.1.2. Tirzepatide

Tirzepatide is a synthetic, single-molecule, 39-amino-acid peptide designed based on the native GIP sequence, but engineered to function as a dual-agonist at both the GIPR and GLP-1R [10]. The peptide sequence includes two non-standard Aib residues at positions 2 and 13 to provide high resistance to DPP-4 enzymatic degradation [8].



Figure 3. Molecular Design and Stability of Therapeutic Incretins

To prolong half-life, a C20 fatty diacid moiety is covalently attached via a hydrophilic linker (gamma-Glu-2xAdo) to a lysine residue at position 20 [10]. This modification enables high-affinity binding to serum albumin, resulting in a therapeutic half-life of approximately 5days [8].

The chemical formula of tirzepatide is $C_{225}H_{348}N_{48}O_{68}$, with a molecular weight of approximately 4813.45Da [10]. Crucially, while tirzepatide exhibits native-like potency at the human GIPR, its affinity for the human GLP-1R is approximately 100-fold lower than that of native GLP-1 [8]. This deliberate imbalance (functioning as a biased agonist) prevents rapid GLP-1R internalization and desensitization, maximizing weight loss and glycemic control while reducing the severity of gastrointestinal side effects [10].



Figure 4. Tirzepatide Dual-Agonist Signaling Bifurcation

3.2. Adipose Tissue Remodeling and Metabolic Off-Target Effects

3.2.1. Mechanisms of White Adipose Tissue Browning

Systemic energy expenditure and metabolic efficiency are deeply influenced by the functional plasticity of adipose tissue depots. While white adipose tissue (WAT) acts primarily as an energy storage site, brown adipose tissue (BAT) facilitates thermogenesis through uncoupling protein 1 (UCP1)-mediated dissipation of the mitochondrial proton gradient [11]. Pharmacological intervention with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, promotes the phenotypic conversion of white adipocytes into high-energy-dissipating beige adipocytes, a process termed browning [11,12].



Figure 5. Central GLP-1R Mediated Adipose Browning Pathway

This tissue remodeling is driven largely via central pathways. Activation of GLP-1 receptors in the central nervous system increases sympathetic nervous system (SNS) outflow to peripheral tissues, stimulating norepinephrine release and subsequent activation of β3-adrenergic receptors on white adipocytes [11]. This adrenergic cascade triggers downstream cyclic adenosine monophosphate (cAMP) signaling, upregulating the transcription of UCP1, peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1α), and cell death-inducing DFFA-like effector A (CIDEA), which collectively govern mitochondrial biogenesis and thermogenic programming [11]. By contrast, glucose-dependent insulinotropic polypeptide (GIP) receptor signaling exerts direct, local actions on adipose tissue [10]. The GIP receptor (GIPR) is highly expressed in adipose tissue, where its activation enhances subcutaneous lipid buffering capacity and increases local blood flow, promoting healthy lipid deposition and preventing ectopic fat accumulation in the liver and skeletal muscle [8,10]. Consequently, the combination of GLP-1-mediated central browning and GIP-mediated subcutaneous lipid clearing prevents lipotoxicity and enhances overall metabolic health [10,4].

3.2.2. Adipogenesis and Adipocyte Hyperplasia Control

Obesity-associated adipose tissue expansion often occurs via pathological hypertrophy, where adipocytes increase in size but become hypoxic, dysfunctional, and highly pro-inflammatory [2]. This hypertrophic state recruits pro-inflammatory immune cells and induces insulin resistance [2]. In contrast, healthy adipose tissue expansion, or hyperplasia, is characterized by the recruitment and differentiation of preadipocytes into small, insulin-sensitive adipocytes [10,11].

Table 2. Functional Contrast of Adipose Tissue Depots under Incretin Receptor Modulation

Adipose Depot / Phenotype	Primary Physiological Role	Downstream Effects of GLP-1R Activation [11]	Downstream Effects of GIPR Activation [8, 10]
White Adipose Tissue (WAT)	Promotes long-term energy storage in the form of neutral triacylglycerols; secretes pro-inflammatory cytokines during pathological expansion	Increases sympathetic nervous system outflow to downregulate inflammatory cytokine secretion and reduce visceral fat mass accumulation	Promotes insulin-mediated lipogenesis and increases local blood flow to safely sequester circulating lipids in healthy subcutaneous depots
Brown Adipose Tissue (BAT)	Facilitates non-shivering thermogenesis via mitochondrial proton gradient dissipation through uncoupling protein 1	Indirectly stimulates brown adipose tissue activation through centrally-mediated sympathetic signaling pathways to elevate basal metabolic rate	Minimally expressed, but local signaling acts in synergy with thyroid pathways to maintain structural integrity and lipid storage in brown adipocytes
Beige Adipose Tissue (BeAT)	Functions as inducible thermogenic foci within white adipose depots; exhibits intermediate morphological and functional traits	Promotes the phenotypic transdifferentiation of white adipocytes to beige adipocytes, upregulating uncoupling protein 1 and mitochondrial density	Works in concert with GLP-1 pathways to enhance systemic metabolic clearing, preventing lipotoxicity in newly developed thermogenic tissues

Semaglutide and tirzepatide assist in restoring healthy adipose tissue architecture by modulating adipogenesis [10,11]. Tirzepatide, through dual agonism, utilizes the insulin-sensitizing effects of GIPR activation to promote insulin-dependent nutrient deposition into subcutaneous depots rather than visceral adipose compartments, reducing circulating free fatty acids and decreasing systemic inflammation [10]. Simultaneously, the suppression of visceral adipose tissue accumulation lowers the expression of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), shifting the adipose secretome toward insulin-sensitizing adipokines, including adiponectin [2,10].

4. Clinical Trials on Incretin Therapy

4.1. Glycemic Efficacy and Glycated Hemoglobin

The clinical registration trials for semaglutide and tirzepatide highlight dose-dependent reductions in glycated hemoglobin (HbA1c) across diverse clinical populations with type 2 diabetes mellitus (T2DM). In the SUSTAIN trial program, once-weekly subcutaneous semaglutide at the therapeutic doses of 1.0mg and 2.0mg consistently reduced HbA1c by 1.5% to 1.8% from baseline, depending on background antidiabetic regimens [12,13]. The glycemic control achieved with semaglutide is mediated by its robust glucose-dependent insulinotropic and glucagonostatic actions, which lower both fasting and postprandial plasma glucose excursions [14].

Tirzepatide shows superior glycemic efficacy when compared directly with selective GLP-1 RAs. In the SURPASS trial program, once-weekly tirzepatide at doses of 5mg, 10mg, and 15mg led to dose-dependent HbA1c reductions ranging from 2.0% to 2.4% [7, 15-18]. This enhanced glycemic response is illustrated in head-to-head clinical assessments, such as the SURPASS-2 trial, where tirzepatide at all evaluated doses surpassed semaglutide 1.0mg in reducing glycated hemoglobin [19].

The molecular synergy of dual agonism underlies this superior performance. While GIP receptor activation directly enhances insulin secretion from pancreatic β-cells through rapid receptor recycling dynamics that prevent desensitization, it also maintains glucagon secretory capacity under hypoglycemic conditions, allowing safe and aggressive glucose lowering without increasing the risk of hypoglycemic events [10,19].

Table 3. Glycemic, Anthropometric, and Cardiovascular Outcomes of Semaglutide and Tirzepatide in Major Trials

Parameter	Semaglutide Clinical Trials [12, 13, 14, 16]	Tirzepatide Clinical Trials [7, 15, 17, 18]
Primary Clinical Trials	SUSTAIN 1–6, STEP 1–4, 8	SURPASS 1–6, SURMOUNT 1–4
HbA1c Reduction Range	↓ 1.5% - 1.8%	↓ 2.0% - 2.4%
Mean Body Weight Reduction	↓ 10% - 15%	↓ 15% - 22.5%
Cardiovascular Outcomes	Superior MACE reduction vs. placebo	Favorable cardiovascular risk profiles

4.2. Anthropometric Reductions and Weight Loss

Body weight regulation with incretin-based agents follows a highly dose-dependent trajectory. In the STEP clinical trial program, which evaluated semaglutide at a dedicated anti-obesity dose of 2.4mg once weekly in adults with overweight or obesity, the mean reduction in total body weight achieved at week 68 was approximately 15% [14,16]. Weight loss trajectories with semaglutide typically show a steep initial decline during the first 28 to 36 weeks of therapy, followed by a gradual deceleration toward a plateau near week 60 [14].

Tirzepatide achieves unprecedented weight reduction by combining GIP and GLP-1 receptor activation. In the SURMOUNT-1 trial, which evaluated adults with obesity or overweight without diabetes, tirzepatide at the maximum dose of 15mg once weekly achieved a mean weight reduction of 20.9% at week 72, with a substantial portion of the cohort achieving a weight loss of 25% or greater [15,18]. The weight loss curve with tirzepatide shows continuous, progressive decline that extends further before reaching a clinical plateau, often around week 52 to 64 [15].

Table 4. Glycemic and Anthropometric Efficacy in Registrational Phase 3 Trials

Clinical Trial	Study Population	Active Interventions	Comparative Controls	Change in HbA1c (%)	Change in Total Body Weight (%)
SUSTAIN-1 [13]	Adults with inadequately controlled type 2 diabetes mellitus	Semaglutide 0.5 mg once weekly or Semaglutide 1.0 mg once weekly	Placebo control group	-1.15% (for 0.5 mg dose) and -1.45% (for 1.0 mg dose)	-3.73% (for 0.5 mg dose) and -4.53% (for 1.0 mg dose)
STEP-2 [16]	Adults with overweight or obesity combined with type 2 diabetes mellitus	Semaglutide 1.0 mg once weekly or Semaglutide 2.4 mg once weekly	Placebo control group	-1.50% (for 1.0 mg dose) and -1.60% (for 2.4 mg dose)	-6.90% (for 1.0 mg dose) and -9.60% (for 2.4 mg dose)
SURPASS [17]	Adults with type 2 diabetes inadequately controlled on metformin	Tirzepatide 5 mg, 10 mg, or 15 mg once weekly	Semaglutide 1.0 mg once weekly	-2.01% (for 5 mg), -2.24% (for 10 mg), and -2.30% (for 15 mg)	-8.50% (for 5 mg), -11.00% (for 10 mg), and -12.40% (for 15 mg)
SURMOUNT-1 [15]	Adults with overweight or obesity without type 2 diabetes mellitus	Tirzepatide 5 mg, 10 mg, or 15 mg once weekly	Placebo control group	Not assessed as a primary endpoint in this trial	-15.00% (for 5 mg), -19.50% (for 10 mg), and -20.90% (for 15 mg)

The mechanical superiority of dual receptor activation in driving weight loss is attributed to the integration of central appetite-regulating networks. Both GLP-1 and GIP receptors are localized on distinct but overlapping neuronal populations in the arcuate nucleus of the hypothalamus and the hindbrain [5]. Simultaneous activation of these receptors induces a synergistic suppression of appetite, reduces food reward pathways, and delays gastric emptying kinetics to a degree that cannot be achieved by selective GLP-1 receptor activation alone at clinically tolerated doses [10, 20-23].

4.3. Tolerability and Gastrointestinal Adverse Events

The exceptional metabolic benefits of semaglutide and tirzepatide must be balanced against their gastrointestinal (GI) side effects. Across all major clinical programs, the most frequently reported adverse events are nausea, vomiting, diarrhea, and constipation [13,16,17]. In the STEP-2 trial, nausea was reported by 15% to 22% of patients receiving semaglutide, with the majority of events characterized as mild-to-moderate in intensity and clustering around the dose-initiation and dose-escalation phases [16]. Similarly, in the SURPASS-3 trial, patients treated with tirzepatide experienced nausea at rates of 12% to 18%, showing a highly comparable tolerability profile [17].

Therapy discontinuation rates due to gastrointestinal adverse events remain relatively low but clinically significant, ranging from 5% to 10% across semaglutide trials and 6% to 9% across tirzepatide trials [16,18]. The clinical data indicate that while tirzepatide achieves substantially greater weight loss and glycemic control, it does not result in a proportional increase in gastrointestinal toxicity [19].

This favorable safety-to-efficacy ratio is explained by the biased agonist properties of tirzepatide at the GLP-1 receptor. Because tirzepatide exhibits approximately 100-fold lower affinity for the GLP-1 receptor than native GLP-1, it minimizes rapid receptor internalization and high-intensity, localized signaling in the hindbrain emetic centers, mitigating severe nausea and vomiting while capitalizing on GIP-mediated metabolic enhancements [10,19].

5. Clinical Management and the Efficacy-Tolerability Trade-Off

5.1. Titration and Mitigation of Adverse Events

The primary clinical strategy to maximize patient retention and minimize gastrointestinal distress is the execution of a gradual, highly individualized dose-escalation protocol. For once-weekly subcutaneous semaglutide, the standardized titration pathway begins at a sub-therapeutic dose of 0.25mg for 4 weeks [7,16]. This initial phase aims to desensitize the peripheral and central receptors responsible for gastrointestinal motility and emesis [5]. The dose is subsequently doubled every 4 weeks to 0.5mg, 1.0mg, and eventually to the maintenance doses of 2.0mg for glycemic control or 2.4mg for weight management [7,16].



Figure 6. Clinical Titration Initiation and Re-titration

Tirzepatide utilizes an identical incremental titration approach. Therapy is initiated at a low dose of 2.5mg once weekly for 4 weeks [7,17]. Clinicians then increase the weekly dose in 2.5mg increments every 4 weeks to a target dose of 5mg, 10mg, or 15mg based on therapeutic response and individual patient tolerability [7,17].

Table 5. Escalation Schemes and Re-Titration Protocols for Once-Weekly Administrations

Titration Step	Semaglutide Weekly Dose	Tirzepatide Weekly Dose	Clinical Purpose / Physiological Mechanism
Initiation Phase (Weeks 1 to 4)	0.25 mg once weekly	2.5 mg once weekly	Desensitizes central emetic centers in the hindbrain and allows gradual peripheral adaptation of enteric receptor kinetics
Escalation Step 1 (Weeks 5 to 8)	0.50 mg once weekly	5.0 mg once weekly	First step to achieve clinical efficacy; monitors for early-stage gastric transit delays and transient mild nausea
Escalation Step 2 (Weeks 9 to 12)	1.00 mg once weekly	7.5 mg once weekly	Establishes stable therapeutic maintenance levels for standard glycemic control and mild weight loss management
Escalation Step 3 (Weeks 13 to 16)	1.70 mg once weekly	10.0 mg once weekly	Intermediate step for patients requiring high-intensity weight loss; allows adaptive re-titration if side effects present
Maintenance Phase (Weeks 17 and beyond)	2.00 mg to 2.40 mg once weekly	12.5 mg to 15.0 mg once weekly	Maximum tolerated dose to drive persistent metabolic improvements and long-term anthropometric maintenance

If a patient experiences severe gastrointestinal distress during any step of the escalation process, clinical guidelines support maintaining the current dose for an additional 4 weeks or temporarily de-escalating to the previously tolerated dose until adaptation occurs [20]. This flexible approach ensures that the rate of receptor saturation matches the biological adaptation rate of the patient's enteric nervous system, preserving treatment adherence.

5.2. Preservation of Lean Mass and Long-Term Metabolic Sustainability

A critical consideration in long-term incretin therapy is the composition of the lost body mass. Rapid, profound weight reduction induced by high-dose GLP-1 receptor agonists or dual co-agonists can result in a disproportionate loss of skeletal muscle mass, also known as fat-free mass, which can account for up to 30% to 40% of the total weight lost in the absence of clinical countermeasures [4,21]. Muscle mass preservation is essential for sustaining resting metabolic rate, ensuring physical functionality, and avoiding the development of sarcopenic obesity, particularly in elderly populations [21].

To optimize body composition outcomes, clinical protocols must integrate nutritional guidance focusing on high-protein intake combined with structured resistance exercise [24]. This lifestyle integration helps preserve skeletal myofibrils while the pharmacotherapy selectively drives fat depletion.

Clinical trial data emphasize that obesity and type 2 diabetes are chronic, progressive metabolic disorders that require sustained intervention [4,18]. Results from the SURMOUNT-4 trial showed that when tirzepatide was withdrawn after 36 weeks of treatment, patients experienced a rapid reversal of weight loss and a return of cardiometabolic risk parameters toward baseline over the subsequent 52 weeks [18]. This rebound effect shows the necessity of viewing incretin therapies as long-term maintenance strategies, where the lowest effective maintenance dose is titrated to sustain metabolic benefit while minimizing the clinical burden of chronic gastrointestinal side effects [18,20].

6. Conclusion

Semaglutide and tirzepatide therapies achieve profound reductions in glycated hemoglobin and historic levels of weight loss that challenge the outcomes traditionally reserved for metabolic bariatric surgery by mimicking and improving the actions of gut-derived incretin hormones. This therapeutic paradigm shifts the focus of type 2 diabetes management from simple glycemic control to a holistic, weight-centric approach that directly mitigates the underlying pathophysiology of ectopic lipid accumulation and chronic low-grade systemic inflammation. However, the clinical translation of these highly potent molecules is constrained by a clear efficacy–tolerability trade-off. The same central and peripheral receptor pathways that suppress appetite and slow gastric transit to

drive weight loss also trigger dose-limiting gastrointestinal toxicities, including nausea, vomiting, diarrhea, and constipation. Managing this trade-off requires clinicians to move away from rigid, maximum-dose and instead implement flexible, patient-centric titration schedules. Clinical practice can optimize long-term treatment adherence and prevent premature discontinuation by prioritizing individual tolerability and maintaining patients on the lowest effective dose that yields meaningful metabolic improvement. Further drug development aims to overcome these tolerability limitations by exploring triple-receptor agonists, such as retatrutide, which targets GIP, GLP-1, and glucagon receptors simultaneously. These next-generation molecules improve metabolic efficacy while potentially minimizing gastrointestinal toxicity through balanced, multi-pathway activation. Tlong-term sustainability of incretin-based metabolic therapies relies on a deep integration of pharmacological precision, proactive side-effect management, and patient-centered clinical care.

References

[1] Garcia FK, Mulder BC, Wagemakers AM, Hazebroek EJ, Verkooijen KT. Understanding metabolic bariatric surgery stigma through the lived experiences of Dutch women. SSM - Qualitative Research in Health. 2026;9:100699.

[2] Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. J Obes Metab Syndr. 2023;32(1):25-45.

[3] Daley S. Obesity and Type 2 Diabetes. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. NBK592412. Available from: https://www.ncbi.nlm.nih.gov/books/NBK592412/.

[4] Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056–1064.

[5] Hayes MR, Borner T, De Jonghe BC. The Role of GIP in the Regulation of GLP-1 Satiety and Nausea. Diabetes. 2021;70(9):1956–1961.

[6] Holst JJ. The incretin system in healthy humans: The role of GIP and GLP-1. Metabolism. 2019;96:46–59.

[7] Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021;12(1):143–157.

[8] Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. Journal of Diabetes Investigation. 2010;1(1-2):8–23.

[9] Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab. 2021;23(Suppl. 3):5–29.

[10] Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315.

[11] Papakonstantinou I, Tsioufis K, Katsi V. Spotlight on the Mechanism of Action of Semaglutide. Curr Issues Mol Biol. 2024;46(12):14514–14541.

[12] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844.

[13] Sorli C, Harashima S, Tsoukas G, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260.

[14] Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–1425.

[15] Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025;15(3):e12734.

[16] Davies M, Færch L, Jeppesen O, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984.

[17] Battelino T, Bergenstal R, Rodríguez A, et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS trial. Lancet Diabetes Endocrinol. 2022;10(6):407–417.

[18] Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2026;186(2):157–167.

[19] Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024;67(7):1206–1222.

[20] Kunutsor SK, Seidu S, Taguiam EJ, Khunti K. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. Drugs. 2025;86(1):11–36.

[21] Wharton S, Lau DC, Vallis M, et al. Glucagon-like Peptide-1 receptor agonists for obesity: Weight loss outcomes, tolerability, side effects, risks. Gastrointest Endosc Clin N Am. 2024;14:1001-1018.

[22] Karimi MA, Gholami Chahkand MS, Dadkhah PA, et al. Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1438318.

[23] Hankosky ER, He X, Malik R, et al. Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes. Diabetes Obes Metab. 2025;27(7):3757–3765.

[24] Tobaiqy M, Elkout H. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. Int J Clin Pharm. 2024;46(2):488–495.